PCSK-9 Monoclonal Antibody Alirocumab Dose-Dependently Decreases Atherosclerosis Development and Enhances the Effects of Atorvastatin in APOE*3Leiden.CETP Mice

Author(s):
Kuhnast, S.; Hoorn, J.W. van der; Pieterman, E.; Sasiela, W.J.; Gusarova, V.; Peyman, A.; Schafer, H.L.; Schwahn, U.; Jukema, J.W. (0000-0002-3246-8359); Princen, H.M.
Published
2013
Publication type
Article / Letter to editor
ArteriosclerosisLipidsLipoproteinsDrugsVascular disease
Date issued
2013-11-26
Language
English
Is part of
Circulation (2013), No. 22
hdl
1887/102848